**Name of Journal: *World Journal of Clinical Cases***

**Manuscript NO: 47598**

**Manuscript Type: REVIEW**

**Colorectal cancer: The epigenetic role of microbiome**

Sabit H *et al*. Microbiome is the second brain

**Hussein Sabit, Emre Cevik, and Huseyin Tombuloglu**

**Hussein Sabit, Emre Cevik, and Huseyin Tombuloglu,** Department of Genetics, Institute for Medical Research and Consultations, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia

**ORCID number:** Hussein Sabit ([0000-0001-9021-8334](https://orcid.org/0000-0001-9021-8334)); Emre Cevik (0000-0003-2075-7361); Huseyin Tombuloglu (0000-0001-8546-2658).

**Author contributions:** Sabit H conceptualized the idea and wrote the manuscript; Cevik E made all the figures and illustrations; Tombuloglu H revised the manuscript.

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Hussein Sabit,** **Professor of Cancer Epigenetics,** Department of Genetics, Institute for Medical Research and Consultations, Imam Abdulrahman Bin Faisal University, PO Box 1982, Dammam 31441, Saudi Arabia. [hhsabit@iau.edu.sa](mailto:hhsabit@iau.edu.sa)

**Telephone:** +966-54-6177974

**Fax:** +966-13-3330333

**Received:** April 1, 2019

**Peer-review started:** April 1, 2019

**First decision:** May 30, 2019

**Revised:** October 23, 2019

**Accepted:** October 30, 2019

**Article in press:**

**Published online:**

**Abstract**

Colorectal cancer (CRC) is the third most common cancer in men (746000 cases per year) and the second most common cancer in women globally (614000 cases per year). The incidence rate of CRC in developed countries (737000 cases per year) is higher than that in less developed countries (624000 cases per year). CRC can arise from genetic causes such as chromosomal instability and microsatellite instability. Several etiologic factors underlie CRC including age, diet, and lifestyle. Gut microbiota represent a proven cause of the disease, where they play pivotal roles in modulating and reshaping the host epigenome. Several active microbial metabolites have been found to drive carcinogenesis, invasion, and metastasis *via* modifying both the methylation landscape along with histone structure in intestinal cells. Gut microbiota, in response to diet, can exert both beneficial and harmful functions in humans, according to the intestinal balance of number and types of these bacteria. Although the intestinal microbial community is diverse among individuals, these microbes cumulatively produce 100-fold more proteins than the human genome itself, which calls for further studies to elaborate on the complicated interaction between these microorganisms and intestinal cells. Therefore, understanding the exact role that gut microbiota play in inducing CRC will help attain reliable strategies to precisely diagnose and treat this fatal disease.

**Key words:** Colorectal; Cancer; Colorectal cancer; Epigenetics; Gut; Microbiota

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Colorectal cancer is serious disease that affects males and females late in their lives. Several etiologic factors trigger colorectal cancer; however, the gut microbiome is responsible of most of the cases. Gut bacteria can produce a variety of chemical compounds that affect intestinal cells and might transform them into malignant ones. In this review, we describe the main mechanisms by which gut microbiota exert these functions.

Sabit H, Cevik E, Tombuloglu H. Colorectal cancer: The epigenetic role of microbiome. *World J Clin Cases* 2019; In press

**INTRODUCTION**

Colorectal cancer (CRC) is one of the primary causes of cancer-related deaths globally[1]. It occurs as a result of complicated sequences involving mutation accumulation that is either genetic or epigenetic[2]. The process of CRC carcinogenesis is a quite slow, starting with minor inflammation followed by adenomatous polyps in the epithelium, and finally adenocarcinoma[3]. Given the crucial role of epigenetic changes in developing CRC, 95% of cases are sporadic *i.e.* appear in patients with no family history for the disease. Meanwhile, minor ratio (3%) is attributed to hereditary nonpolyposis CRC, and 2% of cases are caused by other hereditary disorders such as MYH-associated polyposis and familial adenomatous polyposis[2,4].

Microorganisms occupy almost every part of the human body, armed with a huge number of genes, where it could interact, modulate, or disrupt a wide array of human genes especially in colonic cells[5]. Interestingly, the human microbiome encodes for approximately 100-fold more proteins than the human genome itself. This microbiota comprise 1000 to 1500 bacterial species, and the composition of the microbiome is significantly diverse among individuals[6]. These species belong to just a few phyla: *Firmicutes*, *Bacteroidetes* (most prevalent), *Proteobacteria*, *Verrucomicrobia*, *Actinobacteria*, *Fusobacteria*, and *Cyanobacteria*[7]. Although distribution of the microbiota in terms of types and number is common in healthy individuals, it differs significantly in diseased persons. In addition to bacteria that compose the gut microbiome, eukaryotic fungal species have recently been found to co-exist with bacterial species, the major component of the microbiome[8].

It is well established that gut microbiota play critical roles in the progression of CRC either *via* their metabolites or interaction with their host intestinal epithelial cells[9]. Imbalance of this microbiota has been associated with several disorders including inflammatory bowel disease and CRC[10]. Nonetheless, several studies have related the changes in microbiota to a cause of disease, while others have indicated that these changes are merely a result; however, this issue demands further investigation[11]. In this review, we highlight the recent studies that addresses the causal link between gut microbiota and CRC onset and progression. Meanwhile, the epigenetic changes underlying CRC and its microbial root will also be described.

**CRC**

CRC is one of the most prevalent malignant tumors and the third most common cause of cancer-related death worldwide[12]. It is the third most common malignancy in males and the second in females, with a lifetime risk of about 6%[13]. Being well-developed, CRC can metastasize -even after operation- to distant organs such as the liver and lungs, forming secondary CRC[14]. The common risk factors underlying CRC involve genetics[15], environmental pollution[16], diet[17], age[18], alcohol consumption[19], smoking[20], obesity[21], and physical inactivity[22], with gut microbiota standing alone as a potent risk factor[23] (Figure 1). It is well established that CRC arises due to accumulation of genetic mutations. Large studies showed that approximately 13000 mutations in 67 genes correlate with CRC. Among them, only 12 genes were found to be closely related to CRC[24]. Different types of genomic instability predispose patients to CRC including microsatellite instability (MSI), in which frequent insertions and deletions are prevalent, and chromosomal instability (CIN), in which gain or loss of chromosomes prevail[25]. CIN is responsible for about 85% of CRC cases, where loss of chromosomal segment/arm includes 15q11-q21, 17p12-13, and18q12-21 and gain of chromosomal segment/arm includes 1q32, 7p, 7q, 8q, 13q, 20p, and 20q[26,27].

Several genes are directly correlated with CRC. Examples include *APC* in which inactivation leads to triggering the Wnt signaling pathway to initiate colon polyps which can be benign (*e.g.*, hyperplastic polyp), pre-malignant (*e.g.*, tubular adenoma) or malignant (*e.g.*, colorectal adenocarcinoma)[28]. Furthermore, transforming growth factor receptor 2 *TGFBR2* is involved in almost 30% of CRC cases. The downstream effector of this genes, *i.e.* *KRAS* was found to be activated in 55%-60% of CRC cases. Mismatch repair genes such as *MLH1*, *MSH6*, *MSH2*, and *PMS2* causing frameshift mutations were found to induce *MSI*, triggering the development of CRC[29] (Figure 2).

Epigenetic regulation of gene expression analysis is a validated tool to correlate gene expression changes with cancer development[2,30]. Through the last three decades, solid common knowledge has been established to indicate that the perturbation of epigenetic mechanisms leads to cancer initiation and progression[29,31]. Identification of CRC epigenetic changes has revealed that almost all CRCs have abnormally methylated genes. Although rare data have been provided to highlight the pattern of specific histone modifications in CRC, certain histone modifications (such as acetylation, methylation, and phosphorylation) have been found to work in harmony with DNA methylation to regulate CRC-related gene expression that is involved in cancer initiation and progression[1,32]. Therefore, a deep understanding of epigenetic changes related to CRC pathogenesis might help develop epigenetic-based biomarkers for CRC diagnosis and prognosis, and hence, epigenetic-based therapy[29].

**GUT MICROBIOME**

***Function***

In the normal adult person, the gut microbiota comprise approximately 1014 bacterial cells that live in commensalism with the host, where they substantially facilitate various aspects in the host health and disease[33]. The normal gut microbiota are rich in anaerobic bacteria, which are 100- to 1000-times more than aerobic and facultative anaerobic bacteria, respectively[34]. The colon has a reductive environment devoid of oxygen, which allows *Bacteroidetes* and *Firmicutes* to be the dominant phyla followed by *Actinobacteria* and *Verrucomicrobia*[35]. For bacteria, the colon represents a suitable niche as it provides them with elevated pH, nutrients, and low concentration of bile salts and pancreatic secretions. These conditions, indeed, are favored by bacteria to flourish and proliferate[10]. Commensal bacteria start colonization of the host during birth and continue to variate in number and type along with the host development[36]. It is well established that our gut microbiome is responding to any dietary shift, where switching from polysaccharides-rich diets to that high in animal fat eventually leads to a hasty shift in the gut microbiome[37]. Commonly in the gut, the prevailed microbial product is lipopolysaccharide (LPS), produced by Gram-negative bacteria, function to stimulate the innate immunity, thus, protecting against inflammation that leads to cancer[38] (Table 1).

***Protective role***

Gut microbiota is crucial for numerous characteristics of host biology[10,39]. They enable the host to digest and metabolize indigestible polysaccharides[40]. The gut microbiota plays an important role in maintaining gut homeostasis[41]. Furthermore, gut microbial community also participates effectively in the normal cellular proliferation. To keep its habitat for millions of years, several gut microbiota essentially protect the host against CRC[42]. Reports have indicated that enterotoxigenic *Bacteroides fragilis* is capable of induce apoptosis in CRC cells[42]. Generally, diet is metabolized by microbiota into potent oncometabolites and tumor-suppressive metabolites. Whereas, the same microbiota can digest fiber into short-chain fatty acids (SCFAs)[43]. It is well known that SCFAs have anti-inflammatory properties and can increase the level of colonic regulatory T cells (Tregs) and protect the host against colitis[43,44]. The most common SCFAs produced in the gut are acetate, propionate, and butyrate[45]. Butyrate is one of the important sources of energy, where it provides the cells with 5%-15% of its caloric requirements. *Faecalibacterium prausnitzii* and *Eubacterium rectale* are the main gut bacterial species that produce butyrate[44,46]. Butyrate controls cell proliferation, differentiation, and apoptosis among other functions in colon cells[23,47]. It exerts also a preventive role where it ameliorates the harmful effects of N-nitroso compounds, a product that accumulates in the colon upon intake of heat-treated and processed meat[48] (Figure 3). It has been indicated that *Clostridium* species enhances Treg cell abundance by increasing the production of potent anti-inflammatory molecules such as cytokine interleukin 10 (IL-10)[49]. Lactic acid bacteria have also shown protective properties against CRC *via* different mechanisms that include strengthening the mucosal barrier and altering luminal secretions, resulting in underpinning of the host immune system. Ursodeoxycholic acid (UDCA, ursodiol) is a metabolic byproduct of intestinal bacteria, with a chemical structure that resembles deoxycholic acid (DCA)[50]. While DCA promotes the initiation of CRC, UDCA function to prevent the disease. It was reported that UDCA inhibits the expression of cyclooxygenase-2 (*COX-2*) by Ras-dependent and RAS-independent mechanisms in CRC cells[51]. UDCA prevents colon cells from the harmful effect of DCA *via* inhibiting the DCA-induced extracellular signal-regulated kinase and Raf-1 kinase activity and the activation of epidermal growth factor receptor (EGFR)[52].

***Pro-carcinogenic role***

Microbiota-mediated carcinogenesis is a complex process that takes place through changing host cell proliferation, influencing the host cell immune system, and metabolizing dietary factors[53]. A plethora of research has suggested that an imbalance in normal intestinal microbiota can trigger inflammatory conditions by producing carcinogenic metabolites that lead to cancer formation, and about 16% of human cancers are triggered by bacteria[36,53]. Gut bacteria can attack intestinal epithelial cells to cause inflammation, that in turn, increase the risk of developing CRC[54]. For CRC to occur, the microbiota-host interaction must be dysregulated, resulting in disruption of cellular homoeostasis[55]. The major component of the gut immune system, Peyer’s patch, is robustly influenced by gut microbiota[56]. The host diet can trigger gut microbiota to be involved in the early stages of CRC carcinogenesis[57]. Upon metabolism of saturated fatty acid- and sugar-rich diets, gut bacteria produce harmful procarcinogenic products including polyamines hydrogen sulfide, secondary bile acids such as DCA and lithocholic acid (LCA), and reactive oxygen species (ROS), which induce chronic inflammation, and hence elevate the susceptibility of cells to develop CRC[58]. DCA is a metabolite of the gut microbiota that induces cancer stemness by regulating the muscarinic 3 receptor/Wnt intracellular signaling pathway[59]. It can also trigger the production of Nur77 protein, which is positively correlated with CRC when upregulated[60]. Meanwhile, DCA induces CRC *via* downregulation of miR-199a-5p that degrades *CAC1*, the tumor suppressor gene plays a role in CRC[61]. LCA (aka 3*α*-hydroxy-5β-cholan-24-oic acid), a secondary bile acid synthesized by gut microbiota, is verified to a promoter of CRC[62]. Gut bacteria produce LCA by utilizing DCA[63]. Both LCA and DCA can enhance cancer stemness[64]. Furthermore, LCA and DCA activate the EGFR signaling pathway, inducing DNA damage, and causing oxidative stress, apoptosis, mutation, and activation of the protein kinase C pathway[59].

Trimethylamine (TMA) is solely synthesized by gut microbiota (in humans) from various dietary nutrients including choline and carnitine (found in red meat)[65]. It reacts with flavin monooxygenase to produce trimethylamine-N-oxide (TMAO), a microbial metabolite involved in CRC progression[66]. A high incidence rate of CRC was noticed in omnivorous individuals, as they produce more TMAO compared to vegans and vegetarians who show low incidence rate[67]. The genetic pathway by which TMAO triggers CRC remains unclear.

Furthermore, specific gut bacteria such as *Enterococcus faecalis* was found to induce COX-2, that generates pro-proliferative signals through prostaglandin E(2) (PGE2)[68]. Several Gram-negative bacteria produce LPS that activates TLR4, COX-2, and then PGE2 leading to inhibition of programmed cell death and increase cell proliferation[69]. Moreover, there is an increased resistance to macrophage killing and MAPK activation in those who have the *pks* (polyketide synthase) island in *E. coli* isolated from CRC patients[70]. Activated TLR also enhances angiogenesis through MAPK and NF-*κ*B signaling networks[71] (Figure 4).

Other CRC-related bacterial metabolites were highlighted including fragilysin[72]. This extracellular 20 kDa zinc-dependent metalloproteinase metabolite, produced by *B. fragilis*, could hydrolyze the extracellular domain of E-cadherin and activate the β-catenin nuclear signaling, leading to induction of CRC[73]. Meanwhile fragilysin can damage the tight junction of the intestines, increases intestinal permeability[74]. Colibactin is a bacterial-derived genotoxin first reported in 2006 by Nougayrede and colleagues. It is a hybrid polyketide-non ribosomal peptide produced through an intricate biosynthetic mechanism and encoded by the *pks* pathogenicity island[75]. *E. coli* strains harboring this *pks* island were found to be associated with CRC[76]. Moreover, colibactin, a kind of bacterial toxin synthetized by the *pks* genomic island can trigger chromosomic instability and DNA damage that might lead eventually to CRC[77].

**GUT MICROBIOTA AND EPIGENETIC MODIFICATION**

Several epigenetic changes are common in CRC including DNA methylation, histone modification, and miRNA-mediated post-transcriptional regulation[28,78]. Abnormal epigenetic modifications (AKA epimutations) occur in the promoter regions of tumor-suppressor genes and proto-oncogenes. These epimutations were reported in several malignancies including CRC, where many genes such as *MLH1*, *LKB1*, *APC*, *p16INK4a*, and *GATA4* represent common targets[2,40,79]. Microbial community in our guts are armed with an arsenal of genes that produces millions of proteins, let alone their outpouring of metabolites[67,80]. This microbiota produces low-molecular-weight substances that interact within the human cells with different targets to trigger genomic and epigenomic changes[81]. Research teams everywhere highlight the association between gut microbiota and human diseases; thus, all these diseases should be revisited once again to elucidate the actual role played by microbial community. Being very stable, DNA might not be affected by microbial metabolites, and this is pointing to a more fragile component in our cells; epigenome.

***DNA methylation***

Linking diseases to epigenetic changes was first addressed in 1983[82]. Based on that first note, numerous researches indicated that cancer cells undergo global hypomethylation along with site-specific hypermethylation in the promotors of cancer-related genes[83]. A bunch of reports have indicated that the microbial metabolites can modulate epigenetic landscape of the host gut’s cells *via* modifying the methylation pattern of cancer-related genes, as they represent a validated source of microbial-induced epigenetic change. Thus, the deep understanding of how epigenetic modifications influenced by the gut microbiota take place could offer possible therapeutic targets to prevent and treat CRC[10,80].

In DNA methylation, DNMTs add methyl group (CH3) to the fifth carbon atom in the cytosine residue using the intracellular methyl substrate *S*-Adenosyl methionine (SAM) as a methyl donor to convert the normal cytosine into 5-methylcytosine (5-mC)[84]. Meanwhile, ten-eleven translocation enzyme can reverse this process *via* the oxygenation of 5-mC to produce 5-hydroxymethylcytosine[85]. It is well known that folate is the main source of SAM, and this vitamin could be produced by *Bifidobacterium* and *Lactobacillus*, common probiotic bacteria[86]. Folate is required for DNA methylation (5-methyltetrahydrofolate) or DNA synthesis (5-formyltetrahydrofolate and 5,10-methenyltetrahydrofolate)[87]. A study indicated that volunteers administered *Bifidobacterium* showed a high concentration of folate in their feces, meaning that these probiotic bacteria were capable to generate it and hence, affect DNA methylation pattern[88]. On the other hand, deficiency of folate synthesis might contribute to DNA hypomethylation, which is an established phenomenon in CRC[89]. Meanwhile, pathogenic bacteria such as *Helicobacter pylori* that infects the stomach and causes gastritis or gastric ulcers or in severe infection gastric cancer can induce several epigenetic changes[90]. A comparison between gastric biopsies excised from patients with gastritis (upon infection with *Helicobacter pylori*) and healthy individuals showed that chronic gastritis was associated with promoter hypermethylation of *E-cadherin* (*CDH1*), *MGMT*, *WIF1*, and *MLH1*[91]. Although studies that address the relationship between the microbiome and epigenetic changes in CRC are rare, a population-based study reported that *Fusobacterium* *nucleatum* was associated with genomic hypermutation independent of *CIMP* and *BRAF* mutations[92]. Other study indicated that *Fusobacterium* was correlated with the *CIMP* phenotype, wild-type *TP53*, *hMLH1* methylation, genomic hypermutation, and *CHD7/8* mutation[93]. These studies strongly suggest the contribution of *F. nucleatum* to the epigenetic changes.

***Histone modification***

In addition to DNA methylation changes, histone modification patterns are also altered in human cancers[84,94]. Some bacterial metabolites such as short chain fatty acids (butyrate and acetate) can induce epigenetic changes in colonic cells[23,45]. Butyrate, a byproduct of the fermentation process of undigested dietary carbohydrates and proteins carried out by *Firmicutes*, has been shown to regulate over 4000 genes including many involved in apoptosis and cell cycle regulation[95]. It is known also to inhibit histone deacetylases and induce hyperacetylation of histones, that lead to changes in the expression of critical cell cycle regulatory genes such as *CCND3* and *CDKN1A* in intestinal cells. Butyrate triggers epithelial generation of ROS and function also to suppress NF-*k*B, the protein complex controls DNA transcription[44,96]. Furthermore, *Bacteroides**thetaiotaomicron* stimuli the inflammatory signaling by inhibiting NF-*κ*B pathway through binding to IkB (inhibitor of *κ*B), inhibitory component of the NF-*κ*B pathway[97]. It was reported that infection with *Listeria monocytogenes* (*L. monocytogenes*) can cause deacetylation of histone H3K18 in many genes in colonic cells such as *SMAD1*, *IRF2*, *SMARCA2* and *CXCL12*[98]. *L. monocytogenes* execute the deacetylation process by translocating NAD-dependent deacetylase sirtuin 2 to the host nucleus. By doing so, *L. monocytogenes* epigenetically regulates cell cycle-related genes and modulate the host immune response to enable its invasion[99].

**MICRORNAS (MiRNAs) AND CRC**

MiRNAs are a class of small single-stranded non-coding RNA molecules that are evolutionarily conserved and encoded by nearly 1% of the genome in most species[100]. MiRNAs were found to be involved in initiation, progression, and metastasis of CRC, where it regulate of various cancer-related gene expression at the post-transcriptional level[101]. Deregulated miRNAs identified in different types of cancers might put us a step forward towards understanding the tumor microenvironment, which necessitate deep investigation of their actual role in cancer progression and spreading[102]. Numerous miRNAs were found to be associated with CRC, such as miR-21, Let-7, miR-145, miR-221, miR-17-19 cluster, and miR-143[103]. Table 2 highlights some of miRNAs related to CRC development, progression, and metastasis. Studies addressed the expression levels of different miRNA in CRC, reported that miR-31, miR-20, miR-25, miR-223, miR-133b, miR-92, miR-93, miR-135a, miR-203, miR-183, and miR-17 were upregulated in CRC, while miR-26b, miR-192, miR-145, let-7a, miR-143, miR-215, miR-16, and miR-191 were downregulated in patients with CRC[13,104]. Some miRNAs were suggested to serve as diagnostic markers for CRC, including miR-133a, miR-145, miR-484-5p, miR-139, miR-143, and miR-106a[105], while another study indicated different set of miRNAs that could be used as biomarkers, including miR-125b, miR-125a, miR-143miR-30a-3p, and miR-145[106]. However, this variation in miRNA list might be attributed to the samples used in the identification process (cell line, tissue, blood or stool) and to the techniques employed. Reports also highlight the role of human diet in modulating the expression of miRNA[107]. For example, butyrate was found to regulate the expression of Let-7, miR-18-106a, miR-25-106b, and miR-17-92a in CRC[96]. The later miRNA cluster (miR-17-92a) was found to be associated with c-Myc to inhibit the activity of PTEN and promotes PI3K-Akt-mTOR axis raising the cell survival in early stage adenoma in CRC[108].

**CONCLUSION**

Gut microbiota is an enhancer to our second brain; the intestine. With millions of proteins expressed by the microbiota’s arsenal, human could make use of various kinds of dietary ingredients, that otherwise will be rubbish-in/rubbish-out. Although genetic factors and age play a role in the pathogenesis of CRC, still gut microbiota has the lion’s share in this complicated process. Armed with an enormous number of identified and yet-to-be-identified metabolites, this population of bacteria can modify the gut’s cells methylation pattern and histone structure causing inflammation, that lead eventually to cancer. It is quite important to keep these microorganisms under focus by deeply investigate their intricate communications with our cells. By doing so, we would be able to avoid at least life-threatening diseases such as CRC[1].

**REFERENCES**

1 **Kalady** **MF**, Boland CR, Church JM. Chapter 165 - Inherited Colorectal Cancer and the Genetics of Colorectal Cancer. In: Yeo CJ. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set (Eighth Edition). Philadelphia: Content Repository Only, 2019: 1959-1980 [DOI: 10.1016/B978-0-323-40232-3.00165-5]

2 **Baretti M**, Azad NS. The role of epigenetic therapies in colorectal cancer. *Curr Probl Cancer* 2018; **42**: 530-547 [PMID: 29625794 DOI: 10.1016/j.currproblcancer.2018.03.001]

3 **Wang X**, Yu H, Sun W, Kong J, Zhang L, Tang J, Wang J, Xu E, Lai M, Zhang H. The long non-coding RNA CYTOR drives colorectal cancer progression by interacting with NCL and Sam68. *Mol Cancer* 2018; **17**: 110 [PMID: 30064438 DOI: 10.1186/s12943-018-0860-7]

4 **Lei Z**, Ma X, Li H, Zhang Y, Gao Y, Fan Y, Li X, Chen L, Xie Y, Chen J, Wu S, Tang L, Zhang X. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis. *Urol Oncol* 2018; **36**: 93.e23-93.e37 [PMID: 29066014 DOI: 10.1016/j.urolonc.2017.09.019]

5 **Serino M**. Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections. *J Mol Biol* 2018; **430**: 581-590 [PMID: 29374557 DOI: 10.1016/j.jmb.2018.01.010]

6 **Lee YK**, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? *Science* 2010; **330**: 1768-1773 [PMID: 21205662 DOI: 10.1126/science.1195568]

7 **Sommer F**, Bäckhed F. The gut microbiota--masters of host development and physiology. *Nat Rev Microbiol* 2013; **11**: 227-238 [PMID: 23435359 DOI: 10.1038/nrmicro2974]

8 **Górska A**, Peter S, Willmann M, Autenrieth I, Schlaberg R, Huson DH. Dynamics of the human gut phageome during antibiotic treatment. *Comput Biol Chem* 2018; **74**: 420-427 [PMID: 29567068 DOI: 10.1016/j.compbiolchem.2018.03.011]

9 **Wang J**, Lu R, Fu X, Dan Z, Zhang YG, Chang X, Liu Q, Xia Y, Liu X, Sun J. Novel Regulatory Roles of Wnt1 in Infection-Associated Colorectal Cancer. *Neoplasia* 2018; **20**: 499-509 [PMID: 29626750 DOI: 10.1016/j.neo.2018.03.001]

10 **Kahouli I**, Tomaro-Duchesneau C, Prakash S. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. *J Med Microbiol* 2013; **62**: 1107-1123 [PMID: 23558140 DOI: 10.1099/jmm.0.048975-0]

11 **Harris RA**, Shah R, Hollister EB, Tronstad RR, Hovdenak N, Szigeti R, Versalovic J, Kellermayer R. Colonic Mucosal Epigenome and Microbiome Development in Children and Adolescents. *J Immunol Res* 2016; **2016**: 9170162 [PMID: 27006956 DOI: 10.1155/2016/9170162]

12 **Herbst** CL, Miot JK, Moch SL, Ruff P. Access to colorectal cancer (CRC) chemotherapy and the associated costs in a South African public healthcare patient cohort. *J Cancer Policy* 2018; 15: 18-24 [DOI: 10.1016/j.jcpo.2017.11.005]

13 **Zullig LL**, Smith VA, Jackson GL, Danus S, Schnell M, Lindquist J, Provenzale D, Weinberger M, Kelley MJ, Bosworth HB. Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry. *Clin Colorectal Cancer* 2016; **15**: e199-e204 [PMID: 27301717 DOI: 10.1016/j.clcc.2016.04.005]

14 **Jacobsen A**, Bosch LJW, Martens-de Kemp SR, Carvalho B, Sillars-Hardebol AH, Dobson RJ, de Rinaldis E, Meijer GA, Abeln S, Heringa J, Fijneman RJA, Feenstra KA. Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer. *Sci Rep* 2018; **8**: 7522 [PMID: 29760449 DOI: 10.1038/s41598-018-24982-z]

15 **Brosens LA**, Offerhaus GJ, Giardiello FM. Hereditary Colorectal Cancer: Genetics and Screening. *Surg Clin North Am* 2015; **95**: 1067-1080 [PMID: 26315524 DOI: 10.1016/j.suc.2015.05.004]

16 **López-Abente G**, García-Pérez J, Fernández-Navarro P, Boldo E, Ramis R. Colorectal cancer mortality and industrial pollution in Spain. *BMC Public Health* 2012; **12**: 589 [PMID: 22852770 DOI: 10.1186/1471-2458-12-589]

17 **Baena R**, Salinas P. Diet and colorectal cancer. *Maturitas* 2015; **80**: 258-264 [PMID: 25619144 DOI: 10.1016/j.maturitas.2014.12.017]

18 **Marshall** ML, Roberts M, Susswein LR, Mcgill AK, Xu Z, Klein RT, Hruska KS. High prevalence of pathogenic variants in individuals with colorectal cancer ≤ age 35. *J Clin Oncol* 2018; 36(4\_suppl): 576-576 [DOI: 10.1200/JCO.2018.36.4\_suppl.576]

19 **Phipps AI**, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. *Cancer* 2011; **117**: 4948-4957 [PMID: 21495019 DOI: 10.1002/cncr.26114]

20 **Botteri E**, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. *JAMA* 2008; **300**: 2765-2778 [PMID: 19088354 DOI: 10.1001/jama.2008.839]

21 **Bardou M**, Barkun AN, Martel M. Obesity and colorectal cancer. *Gut* 2013; **62**: 933-947 [PMID: 23481261 DOI: 10.1136/gutjnl-2013-304701]

22 **Silva DAS**, Tremblay MS, Souza MFM, Mooney M, Naghavi M, Malta DC. Mortality and years of life lost by colorectal cancer attributable to physical inactivity in Brazil (1990-2015): Findings from the Global Burden of Disease Study. *PLoS One* 2018; **13**: e0190943 [PMID: 29390002 DOI: 10.1371/journal.pone.0190943]

23 **Bishop KS**, Xu H, Marlow G. Epigenetic Regulation of Gene Expression Induced by Butyrate in Colorectal Cancer: Involvement of MicroRNA. *Genet Epigenet* 2017; **9**: 1179237X17729900 [PMID: 28979170 DOI: 10.1177/1179237X17729900]

24 **Cummins JM**, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE. The colorectal microRNAome. *Proc Natl Acad Sci U S A* 2006; **103**: 3687-3692 [PMID: 16505370 DOI: 10.1073/pnas.0511155103]

25 **Jass JR**. Molecular heterogeneity of colorectal cancer: Implications for cancer control. *Surg Oncol* 2007; **16 Suppl 1**: S7-S9 [PMID: 18023574 DOI: 10.1016/j.suronc.2007.10.039]

26 **Hermsen M**, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, Roemen G, Arends JW, Williams R, Giaretti W, De Goeij A, Meijer G. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. *Gastroenterology* 2002; **123**: 1109-1119 [PMID: 12360473 DOI: 10.1053/gast.2002.36051]

27 **Douglas EJ**, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W, Tomlinson IP, Carter NP. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. *Cancer Res* 2004; **64**: 4817-4825 [PMID: 15256451 DOI: 10.1158/0008-5472.CAN-04-0328]

28 **Vogelstein B**, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988; **319**: 525-532 [PMID: 2841597 DOI: 10.1056/NEJM198809013190901]

29 **Söreide K**, Janssen EA, Söiland H, Körner H, Baak JP. Microsatellite instability in colorectal cancer. *Br J Surg* 2006; **93**: 395-406 [PMID: 16555243 DOI: 10.1002/bjs.5328]

30 **Nguyen HT**, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (review). *Oncol Lett* 2018; 16: 9-18 [DOI: 10.3892/ol.2018.8679]

31 **Luo N**, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. *Nat Commun* 2018; **9**: 248 [PMID: 29339738 DOI: 10.1038/s41467-017-02630-w]

32 **Druliner BR**, Wang P, Bae T, Baheti S, Slettedahl S, Mahoney D, Vasmatzis N, Xu H, Kim M, Bockol M, O'Brien D, Grill D, Warner N, Munoz-Gomez M, Kossick K, Johnson R, Mouchli M, Felmlee-Devine D, Washechek-Aletto J, Smyrk T, Oberg A, Wang J, Chia N, Abyzov A, Ahlquist D, Boardman LA. Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. *Sci Rep* 2018; **8**: 3161 [PMID: 29453410 DOI: 10.1038/s41598-018-21525-4]

33 **Shenderov BA**. Gut indigenous microbiota and epigenetics. *Microb Ecol Health Dis* 2012; **23** [PMID: 23990811 DOI: 10.3402/mehd.v23i0.17195]

34 **Li DY**, Tang WHW. Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease. *Semin Nephrol* 2018; **38**: 193-205 [PMID: 29602401 DOI: 10.1016/j.semnephrol.2018.01.008]

35 **Tomazetto G**, Hahnke S, Wibberg D, Pühler A, Klocke M, Schlüter A. *Proteiniphilum saccharofermentans* str. M3/6T isolated from a laboratory biogas reactor is versatile in polysaccharide and oligopeptide utilization as deduced from genome-based metabolic reconstructions. *Biotechnol Rep (Amst)* 2018; **18**: e00254 [PMID: 29892569 DOI: 10.1016/j.btre.2018.e00254]

36 **Haag LM**, Fischer A, Otto B, Plickert R, Kühl AA, Göbel UB, Bereswill S, Heimesaat MM. Intestinal microbiota shifts towards elevated commensal Escherichia coli loads abrogate colonization resistance against Campylobacter jejuni in mice. *PLoS One* 2012; **7**: e35988 [PMID: 22563475 DOI: 10.1371/journal.pone.0035988]

37 **Lovegrove A**, Edwards CH, De Noni I, Patel H, El SN, Grassby T, Zielke C, Ulmius M, Nilsson L, Butterworth PJ, Ellis PR, Shewry PR. Role of polysaccharides in food, digestion, and health. *Crit Rev Food Sci Nutr* 2017; **57**: 237-253 [PMID: 25921546 DOI: 10.1080/10408398.2014.939263]

38 **Liang D**, Leung RK, Guan W, Au WW. Involvement of gut microbiome in human health and disease: brief overview, knowledge gaps and research opportunities. *Gut Pathog* 2018; **10**: 3 [PMID: 29416567 DOI: 10.1186/s13099-018-0230-4]

39 **Sun J**, Kato I. Gut microbiota, inflammation and colorectal cancer. *Genes Dis* 2016; **3**: 130-143 [PMID: 28078319 DOI: 10.1016/j.gendis.2016.03.004]

40 **Yadav R**, Kumar V, Baweja M, Shukla P. Gene editing and genetic engineering approaches for advanced probiotics: A review. *Crit Rev Food Sci Nutr* 2018; **58**: 1735-1746 [PMID: 28071925 DOI: 10.1080/10408398.2016.1274877]

41 **Mori G**, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Passardi A, Casadei Gardini A, Frassineti GL, Gaiarsa S, Albertini AM, Ranzani GN, Calistri D, Pasca MR. Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. *Sci Rep* 2018; **8**: 10329 [PMID: 29985435 DOI: 10.1038/s41598-018-28671-9]

42 **Bober JR**, Beisel CL, Nair NU. Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications. *Annu Rev Biomed Eng* 2018; **20**: 277-300 [PMID: 29528686 DOI: 10.1146/annurev-bioeng-062117-121019]

43 **Nagpal R**, Wang S, Ahmadi S, Hayes J, Gagliano J, Subashchandrabose S, Kitzman DW, Becton T, Read R, Yadav H. Human-origin probiotic cocktail increases short-chain fatty acid production via modulation of mice and human gut microbiome. *Sci Rep* 2018; **8**: 12649 [PMID: 30139941 DOI: 10.1038/s41598-018-30114-4]

44 **Bultman SJ**. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. *Mol Nutr Food Res* 2017; **61** [PMID: 27138454 DOI: 10.1002/mnfr.201500902]

45 **Bourassa MW**, Alim I, Bultman SJ, Ratan RR. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? *Neurosci Lett* 2016; **625**: 56-63 [PMID: 26868600 DOI: 10.1016/j.neulet.2016.02.009]

46 **Wang Q**, Li L, Xu R. A systems biology approach to predict and characterize human gut microbial metabolites in colorectal cancer. *Sci Rep* 2018; **8**: 6225 [PMID: 29670137 DOI: 10.1038/s41598-018-24315-0]

47 **Landi D**, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, Canzian F, Barale R, Gemignani F, Landi S. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. *Mutat Res* 2011; **717**: 109-115 [PMID: 20971123 DOI: 10.1016/j.mrfmmm.2010.10.002]

48 **Ferguson LR**. Meat and cancer. *Meat Sci* 2010; **84**: 308-313 [PMID: 20374790 DOI: 10.1016/j.meatsci.2009.06.032]

49 **Cui H**, Cai Y, Wang L, Jia B, Li J, Zhao S, Chu X, Lin J, Zhang X, Bian Y, Zhuang P. Berberine Regulates Treg/Th17 Balance to Treat Ulcerative Colitis Through Modulating the Gut Microbiota in the Colon. *Front Pharmacol* 2018; **9**: 571 [PMID: 29904348 DOI: 10.3389/fphar.2018.00571]

50 **Pearson T**, Caporaso JG, Yellowhair M, Bokulich NA, Padi M, Roe DJ, Wertheim BC, Linhart M, Martinez JA, Bilagody C, Hornstra H, Alberts DS, Lance P, Thompson PA. Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development. *Cancer Med* 2019; **8**: 617-628 [PMID: 30652422 DOI: 10.1002/cam4.1965]

51 **Wang D**, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. *Oncogene* 2010; **29**: 781-788 [PMID: 19946329 DOI: 10.1038/onc.2009.421]

52 **Khare S**, Cerda S, Wali RK, Von Lintig FC, Tretiakova M, Joseph L, Stoiber D, Cohen G, Nimmagadda K, Hart J, Sitrin MD, Boss GR, Bissonnette M. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. *Cancer Res* 2003; 63: 3517-3523 [PMID: 12839936 DOI: 10.1016/S0016-5085(03)83066-4]

53 **Cani PD**, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 671-682 [PMID: 29844585 DOI: 10.1038/s41575-018-0025-6]

54 **Zhang Y**, Yu X, Yu E, Wang N, Cai Q, Shuai Q, Yan F, Jiang L, Wang H, Liu J, Chen Y, Li Z, Jiang Q. Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study. *BMC Microbiol* 2018; **18**: 92 [PMID: 30157754 DOI: 10.1186/s12866-018-1232-6]

55 **Rajilić-Stojanović M**. Function of the microbiota. *Best Pract Res Clin Gastroenterol* 2013; **27**: 5-16 [PMID: 23768548 DOI: 10.1016/j.bpg.2013.03.006]

56 **Shi N**, Li N, Duan X, Niu H. Interaction between the gut microbiome and mucosal immune system. *Mil Med Res* 2017; **4**: 14 [PMID: 28465831 DOI: 10.1186/s40779-017-0122-9]

57 **Culpepper** **T**, Ukhanova M, Wang X, Sun Y, Mai V. Associations between diet, gut microbiota and markers of CRC risk. *Cancer & Metabolism* 2014; 2: 2049-3002 [DOI: 10.1186/2049-3002-2-S1-P45]

58 **Yang Y**, Nirmagustina DE, Kumrungsee T, Okazaki Y, Tomotake H, Kato N. Feeding of the water extract from Ganoderma lingzhi to rats modulates secondary bile acids, intestinal microflora, mucins, and propionate important to colon cancer. *Biosci Biotechnol Biochem* 2017; **81**: 1796-1804 [PMID: 28661219 DOI: 10.1080/09168451.2017.1343117]

59 **Centuori SM**, Martinez JD. Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. *Dig Dis Sci* 2014; **59**: 2367-2380 [PMID: 25027205 DOI: 10.1007/s10620-014-3190-7]

60 **Wang JR**, Gan WJ, Li XM, Zhao YY, Li Y, Lu XX, Li JM, Wu H. Orphan nuclear receptor Nur77 promotes colorectal cancer invasion and metastasis by regulating MMP-9 and E-cadherin. *Carcinogenesis* 2014; **35**: 2474-2484 [PMID: 25064356 DOI: 10.1093/carcin/bgu157]

61 **Kong Y**, Bai PS, Sun H, Nan KJ, Chen NZ, Qi XG. The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer. *Int J Biochem Cell Biol* 2012; **44**: 2321-2332 [PMID: 22903020 DOI: 10.1016/j.biocel.2012.08.006]

62 **Ocvirk S**, O'Keefe SJ. Influence of Bile Acids on Colorectal Cancer Risk: Potential Mechanisms Mediated by Diet - Gut Microbiota Interactions. *Curr Nutr Rep* 2017; **6**: 315-322 [PMID: 29430336 DOI: 10.1007/s13668-017-0219-5]

63 **Mikó E**, Vida A, Kovács T, Ujlaki G, Trencsényi G, Márton J, Sári Z, Kovács P, Boratkó A, Hujber Z, Csonka T, Antal-Szalmás P, Watanabe M, Gombos I, Csoka B, Kiss B, Vígh L, Szabó J, Méhes G, Sebestyén A, Goedert JJ, Bai P. Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness. *Biochim Biophys Acta Bioenerg* 2018; **1859**: 958-974 [PMID: 29655782 DOI: 10.1016/j.bbabio.2018.04.002]

64 **Farhana L**, Nangia-Makker P, Arbit E, Shango K, Sarkar S, Mahmud H, Hadden T, Yu Y, Majumdar AP. Bile acid: a potential inducer of colon cancer stem cells. *Stem Cell Res Ther* 2016; **7**: 181 [PMID: 27908290 DOI: 10.1186/s13287-016-0439-4]

65 **Landfald B**, Valeur J, Berstad A, Raa J. Microbial trimethylamine-*N*-oxide as a disease marker: something fishy? *Microb Ecol Health Dis* 2017; **28**: 1327309 [PMID: 28588431 DOI: 10.1080/16512235.2017.1327309]

66 **Liu ZY**, Tan XY, Li QJ, Liao GC, Fang AP, Zhang DM, Chen PY, Wang XY, Luo Y, Long JA, Zhong RH, Zhu HL. Trimethylamine N-oxide, a gut microbiota-dependent metabolite of choline, is positively associated with the risk of primary liver cancer: a case-control study. *Nutr Metab (Lond)* 2018; **15**: 81 [PMID: 30479648 DOI: 10.1186/s12986-018-0319-2]

67 **Zou S**, Fang L, Lee MH. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. *Gastroenterol Rep (Oxf)* 2018; **6**: 1-12 [PMID: 29479437 DOI: 10.1093/gastro/gox031]

68 **Wang X**, Allen TD, Yang Y, Moore DR, Huycke MM. Cyclooxygenase-2 generates the endogenous mutagen trans-4-hydroxy-2-nonenal in Enterococcus faecalis-infected macrophages. *Cancer Prev Res (Phila)* 2013; **6**: 206-216 [PMID: 23321929 DOI: 10.1158/1940-6207.CAPR-12-0350]

69 **Floch** **MH**, Ringel Y, Walker WA. The Microbiota in Gastrointestinal Pathophysiology: Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis. US: Academic Press, 2016

70 **Veziant J**, Gagnière J, Jouberton E, Bonnin V, Sauvanet P, Pezet D, Barnich N, Miot-Noirault E, Bonnet M. Association of colorectal cancer with pathogenic Escherichia coli: Focus on mechanisms using optical imaging. *World J Clin Oncol* 2016; **7**: 293-301 [PMID: 27298769 DOI: 10.5306/wjco.v7.i3.293]

71 **Zou J**, Shankar N. Roles of TLR/MyD88/MAPK/NF-κB Signaling Pathways in the Regulation of Phagocytosis and Proinflammatory Cytokine Expression in Response to E. faecalis Infection. *PLoS One* 2015; **10**: e0136947 [PMID: 26317438 DOI: 10.1371/journal.pone.0136947]

72 **Boleij A**, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC, Platz EA, Pardoll DM, Sears CL. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. *Clin Infect Dis* 2015; **60**: 208-215 [PMID: 25305284 DOI: 10.1093/cid/ciu787]

73 **Shiryaev SA**, Remacle AG, Chernov AV, Golubkov VS, Motamedchaboki K, Muranaka N, Dambacher CM, Capek P, Kukreja M, Kozlov IA, Perucho M, Cieplak P, Strongin AY. Substrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface. *J Biol Chem* 2013; **288**: 34956-34967 [PMID: 24145028 DOI: 10.1074/jbc.M113.516153]

74 **Lv Y**, Ye T, Wang HP, Zhao JY, Chen WJ, Wang X, Shen CX, Wu YB, Cai YK. Suppression of colorectal tumorigenesis by recombinant *Bacteroides fragilis* enterotoxin-2 *in vivo*. *World J Gastroenterol* 2017; **23**: 603-613 [PMID: 28216966 DOI: 10.3748/wjg.v23.i4.603]

75 **Nougayrède JP**, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. *Science* 2006; **313**: 848-851 [PMID: 16902142 DOI: 10.1126/science.1127059]

76 **Buc E**, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. *PLoS One* 2013; **8**: e56964 [PMID: 23457644 DOI: 10.1371/journal.pone.0056964]

77 **Cuevas-Ramos G**, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. *Proc Natl Acad Sci U S A* 2010; **107**: 11537-11542 [PMID: 20534522 DOI: 10.1073/pnas.1001261107]

78 **Wang Y**, Zhang R, Wu D, Lu Z, Sun W, Cai Y, Wang C, Jin J. Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. *J Exp Clin Cancer Res* 2013; **32**: 8 [PMID: 23394073 DOI: 10.1186/1756-9966-32-8]

79 **Lannagan TRM**, Lee YK, Wang T, Roper J, Bettington ML, Fennell L, Vrbanac L, Jonavicius L, Somashekar R, Gieniec K, Yang M, Ng JQ, Suzuki N, Ichinose M, Wright JA, Kobayashi H, Putoczki TL, Hayakawa Y, Leedham SJ, Abud HE, Yilmaz ÖH, Marker J, Klebe S, Wirapati P, Mukherjee S, Tejpar S, Leggett BA, Whitehall VLJ, Worthley DL, Woods SL. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. *Gut* 2019; **68**: 684-692 [PMID: 29666172 DOI: 10.1136/gutjnl-2017-315920]

80 **Raskov H**, Burcharth J, Pommergaard HC. Linking Gut Microbiota to Colorectal Cancer. *J Cancer* 2017; **8**: 3378-3395 [PMID: 29151921 DOI: 10.7150/jca.20497]

81 **Gerhauser C**. Impact of dietary gut microbial metabolites on the epigenome. *Philos Trans R Soc Lond B Biol Sci* 2018; **373** [PMID: 29685968 DOI: 10.1098/rstb.2017.0359]

82 **Bruserud Ø**, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. *Curr Pharm Biotechnol* 2007; **8**: 388-400 [PMID: 18289048 DOI: 10.2174/138920107783018417]

83 **Shen L**, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X, Waterland RA, Issa JP. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. *PLoS Genet* 2007; **3**: 2023-2036 [PMID: 17967063 DOI: 10.1371/journal.pgen.0030181]

84 **Sandoval-Basilio J**, González-González R, Bologna-Molina R, Isiordia-Espinoza M, Leija-Montoya G, Alcaraz-Estrada SL, Serafín-Higuera I, González-Ramírez J, Serafín-Higuera N. Epigenetic mechanisms in odontogenic tumors: A literature review. *Arch Oral Biol* 2018; **87**: 211-217 [PMID: 29310033 DOI: 10.1016/j.archoralbio.2017.12.029]

85 **Cheng YW**, Chou CJ, Yang PM. Ten-eleven translocation 1 (TET1) gene is a potential target of miR-21-5p in human colorectal cancer. *Surg Oncol* 2018; **27**: 76-81 [PMID: 29549908 DOI: 10.1016/j.suronc.2017.12.004]

86 **Kopp M**, Dürr K, Steigleder M, Clavel T, Rychlik M. Development of stable isotope dilution assays for the quantitation of intra- and extracellular folate patterns of Bifidobacterium adolescentis. *J Chromatogr A* 2016; **1469**: 48-59 [PMID: 27692648 DOI: 10.1016/j.chroma.2016.09.048]

87 **Zhou HR**, Zhang FF, Ma ZY, Huang HW, Jiang L, Cai T, Zhu JK, Zhang C, He XJ. Folate polyglutamylation is involved in chromatin silencing by maintaining global DNA methylation and histone H3K9 dimethylation in Arabidopsis. *Plant Cell* 2013; **25**: 2545-2559 [PMID: 23881414 DOI: 10.1105/tpc.113.114678]

88 **Pompei A**, Cordisco L, Amaretti A, Zanoni S, Matteuzzi D, Rossi M. Folate production by bifidobacteria as a potential probiotic property. *Appl Environ Microbiol* 2007; **73**: 179-185 [PMID: 17071792 DOI: 10.1128/aem.01763-06]

89 **Wasson GR**, McGlynn AP, McNulty H, O'Reilly SL, McKelvey-Martin VJ, McKerr G, Strain JJ, Scott J, Downes CS. Global DNA and p53 region-specific hypomethylation in human colonic cells is induced by folate depletion and reversed by folate supplementation. *J Nutr* 2006; **136**: 2748-2753 [PMID: 17056795 DOI: 10.1093/jn/136.11.2748]

90 **Cheng AS**, Li MS, Kang W, Cheng VY, Chou JL, Lau SS, Go MY, Lee CC, Ling TK, Ng EK, Yu J, Huang TH, To KF, Chan MW, Sung JJ, Chan FK. Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. *Gastroenterology* 2013; **144**: 122-133.e9 [PMID: 23058321 DOI: 10.1053/j.gastro.2012.10.002]

91 **Kawanaka M**, Watari J, Kamiya N, Yamasaki T, Kondo T, Toyoshima F, Ikehara H, Tomita T, Oshima T, Fukui H, Daimon T, Das KM, Miwa H. Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial. *Br J Cancer* 2016; **114**: 21-29 [PMID: 26671747 DOI: 10.1038/bjc.2015.418]

92 **Koi M**, Okita Y, Carethers JM. *Fusobacterium nucleatum* Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations. *J Anus Rectum Colon* 2018; **2**: 37-46 [PMID: 30116794 DOI: 10.23922/jarc.2017-055]

93 **Inamura K**. Colorectal Cancers: An Update on Their Molecular Pathology. *Cancers (Basel)* 2018; **10** [PMID: 29361689 DOI: 10.3390/cancers10010026]

94 **Supic G**, Zeljic K, Magic Z. Chapter 15 - Epigenetic Nutraceuticals in Cancer Treatment, In: Holban AM, Grumezescu AM. Therapeutic Foods. Academic Press, 2018: 449-493 [DOI: 10.1016/B978-0-12-811517-6.00015-5]

95 **Kurita-Ochiai T**, Hashizume T, Yonezawa H, Ochiai K, Yamamoto M. Characterization of the effects of butyric acid on cell proliferation, cell cycle distribution and apoptosis. *FEMS Immunol Med Microbiol* 2006; **47**: 67-74 [PMID: 16706789 DOI: 10.1111/j.1574-695X.2006.00066.x]

96 **Hu S**, Liu L, Chang EB, Wang JY, Raufman JP. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. *Mol Cancer* 2015; **14**: 180 [PMID: 26463716 DOI: 10.1186/s12943-015-0450-x]

97 **Jung J**, Ko SH, Yoo do Y, Lee JY, Kim YJ, Choi SM, Kang KK, Yoon HJ, Kim H, Youn J, Kim JM. 5,7-Dihydroxy-3,4,6-trimethoxyflavone inhibits intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 via the Akt and nuclear factor-κB-dependent pathway, leading to suppression of adhesion of monocytes and eosinophils to bronchial epithelial cells. *Immunology* 2012; **137**: 98-113 [PMID: 22862554 DOI: 10.1111/j.1365-2567.2012.03618.x]

98 **Minarovits** **J**, Niller HH. Patho-Epigenetics of Infectious Disease. Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 879). Cham: Springer, 2015 [DOI: 10.1007/978-3-319-24738-0]

99 **Jing H**, Lin H. Sirtuins in epigenetic regulation. *Chem Rev* 2015; **115**: 2350-2375 [PMID: 25804908 DOI: 10.1021/cr500457h]

100 **Migault M**, Donnou-Fournet E, Galibert MD, Gilot D. Definition and identification of small RNA sponges: Focus on miRNA sequestration. *Methods* 2017; **117**: 35-47 [PMID: 27876678 DOI: 10.1016/j.ymeth.2016.11.012]

101 **Balmayor** ER, Font Tellado S, Van Griensven M, 2.26 MicroRNA as Biomaterial. In: Ducheyne P. Comprehensive Biomaterials II. 2nd Ed. Elsevier: Oxford, 2017: 558-570 [DOI: 10.1016/B978-0-12-803581-8.09320-6]

102 **Kai K**, Dittmar RL, Sen S. Secretory microRNAs as biomarkers of cancer. *Semin Cell Dev Biol* 2018; **78**: 22-36 [PMID: 29258963 DOI: 10.1016/j.semcdb.2017.12.011]

103 **Strubberg AM**, Madison BB. MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. *Dis Model Mech* 2017; **10**: 197-214 [PMID: 28250048 DOI: 10.1242/dmm.027441]

104 **Kim SW**. [The Role of MicroRNAs in Colorectal Cancer]. *Korean J Gastroenterol* 2017; **69**: 206-211 [PMID: 28449421 DOI: 10.4166/kjg.2017.69.4.206]

105 **Schee K**, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. *BMC Cancer* 2012; **12**: 505 [PMID: 23121918 DOI: 10.1186/1471-2407-12-505]

106 **Cekaite L**, Eide PW, Lind GE, Skotheim RI, Lothe RA. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. *Oncotarget* 2016; **7**: 6476-6505 [PMID: 26623728 DOI: 10.18632/oncotarget.6390]

107 **Karius T**, Schnekenburger M, Dicato M, Diederich M. MicroRNAs in cancer management and their modulation by dietary agents. *Biochem Pharmacol* 2012; **83**: 1591-1601 [PMID: 22342289 DOI: 10.1016/j.bcp.2012.02.004]

108 **Gao P**, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature* 2009; **458**: 762-765 [PMID: 19219026 DOI: 10.1038/nature07823]

109 **Jacouton E**, Chain F, Sokol H, Langella P, Bermúdez-Humarán LG. Probiotic Strain *Lactobacillus casei* BL23 Prevents Colitis-Associated Colorectal Cancer. *Front Immunol* 2017; **8**: 1553 [PMID: 29209314 DOI: 10.3389/fimmu.2017.01553]

110 **Kåhrström CT**. Bacterial pathogenesis: E. coli claims the driving seat for cancer. *Nat Rev Cancer* 2012; **12**: 658-659 [PMID: 22972456 DOI: 10.1038/nrc3363]

111 **Shang FM**, Liu HL. *Fusobacterium nucleatum* and colorectal cancer: A review. *World J Gastrointest Oncol* 2018; **10**: 71-81 [PMID: 29564037 DOI: 10.4251/wjgo.v10.i3.71]

112 **Rivière A**, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front Microbiol* 2016; **7**: 979 [PMID: 27446020 DOI: 10.3389/fmicb.2016.00979]

113 **Purcell RV**, Pearson J, Aitchison A, Dixon L, Frizelle FA, Keenan JI. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. *PLoS One* 2017; **12**: e0171602 [PMID: 28151975 DOI: 10.1371/journal.pone.0171602]

114 **Tsai CE**, Chiu CT, Rayner CK, Wu KL, Chiu YC, Hu ML, Chuah SK, Tai WC, Liang CM, Wang HM. Associated factors in Streptococcus bovis bacteremia and colorectal cancer. *Kaohsiung J Med Sci* 2016; **32**: 196-200 [PMID: 27185602 DOI: 10.1016/j.kjms.2016.03.003]

115 **Melton-Witt JA**, Bentsen LM, Tweten RK. Identification of functional domains of Clostridium septicum alpha toxin. *Biochemistry* 2006; **45**: 14347-14354 [PMID: 17128973 DOI: 10.1021/bi061334p]

116 **Huycke MM**, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. *Carcinogenesis* 2002; **23**: 529-536 [PMID: 11895869 DOI: 10.1093/carcin/23.3.529]

117 **Asakuma S**, Hatakeyama E, Urashima T, Yoshida E, Katayama T, Yamamoto K, Kumagai H, Ashida H, Hirose J, Kitaoka M. Physiology of consumption of human milk oligosaccharides by infant gut-associated bifidobacteria. *J Biol Chem* 2011; **286**: 34583-34592 [PMID: 21832085 DOI: 10.1074/jbc.M111.248138]

118 **Papastergiou V**, Karatapanis S, Georgopoulos SD. Helicobacter pylori and colorectal neoplasia: Is there a causal link? *World J Gastroenterol* 2016; **22**: 649-658 [PMID: 26811614 DOI: 10.3748/wjg.v22.i2.649]

119 **Martín R**, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM, Sokol H, Bermúdez-Humarán LG, Thomas M, Langella P. Functional Characterization of Novel *Faecalibacterium prausnitzii* Strains Isolated from Healthy Volunteers: A Step Forward in the Use of *F. prausnitzii* as a Next-Generation Probiotic. *Front Microbiol* 2017; **8**: 1226 [PMID: 28713353 DOI: 10.3389/fmicb.2017.01226]

120 **Chen L**, Tai WC, Brar MS, Leung FC, Hsiao WL. Tumor grafting induces changes of gut microbiota in athymic nude mice in the presence and absence of medicinal Gynostemma saponins. *PLoS One* 2015; **10**: e0126807 [PMID: 25992551 DOI: 10.1371/journal.pone.0126807]

121 **Zhou Z**, Chen J, Yao H, Hu H. *Fusobacterium* and Colorectal Cancer. *Front Oncol* 2018; **8**: 371 [PMID: 30374420 DOI: 10.3389/fonc.2018.00371]

122 **McFarlane ME**, Coard KC. Actinomycosis of the colon with invasion of the abdominal wall: An uncommon presentation of a colonic tumour. *Int J Surg Case Rep* 2010; **1**: 9-11 [PMID: 22096664 DOI: 10.1016/j.ijscr.2010.07.002]

123 **Deng X**, Li Z, Li G, Li B, Jin X, Lyu G. Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy. *Front Microbiol* 2018; **9**: 1607 [PMID: 30065719 DOI: 10.3389/fmicb.2018.01607]

124 **Xiao G**, Tang H, Wei W, Li J, Ji L, Ge J. Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer. *Gastroenterol Res Pract* 2014; **2014**: 364549 [PMID: 25435873 DOI: 10.1155/2014/364549]

125 **Díaz R**, Silva J, García JM, Lorenzo Y, García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F, Domínguez G. Deregulated expression of miR-106a predicts survival in human colon cancer patients. *Genes Chromosomes Cancer* 2008; **47**: 794-802 [PMID: 18521848 DOI: 10.1002/gcc.20580]

126 **Karaayvaz M**, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K, Ju J. Prognostic significance of miR-215 in colon cancer. *Clin Colorectal Cancer* 2011; **10**: 340-347 [PMID: 21752725 DOI: 10.1016/j.clcc.2011.06.002]

127 **Weissmann-Brenner A**, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, Kundel Y, Morgenstern S, Halperin M, Niv Y, Brenner B. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. *Int J Oncol* 2012; **40**: 2097-2103 [PMID: 22426940 DOI: 10.3892/ijo.2012.1403]

128 **Gao J**, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, Shen L, Yu J. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. *Oncogene* 2015; **34**: 4142-4152 [PMID: 25362853 DOI: 10.1038/onc.2014.348]

129 **Mokutani Y**, Uemura M, Munakata K, Okuzaki D, Haraguchi N, Takahashi H, Nishimura J, Hata T, Murata K, Takemasa I, Mizushima T, Doki Y, Mori M, Yamamoto H. Down-Regulation of microRNA-132 is Associated with Poor Prognosis of Colorectal Cancer. *Ann Surg Oncol* 2016; **23**: 599-608 [PMID: 26868958 DOI: 10.1245/s10434-016-5133-3]

130 **Ma Y**, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W, Qin H. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. *Gut* 2012; **61**: 1447-1453 [PMID: 22052060 DOI: 10.1136/gutjnl-2011-301122]

131 **Wang X**, Wang J, Ma H, Zhang J, Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. *Med Oncol* 2012; **29**: 919-927 [PMID: 21390519 DOI: 10.1007/s12032-011-9880-5]

132 **Shen** ZL, Wang B, Jiang KW, Ye CX, Cheng C, Yan YC, Zhang JZ, Yang Y, Gao ZD, Ye YJ, Wang S. Downregulation of miR-199b is associated with distant metastasis in colorectal cancer via activation of SIRT1 and inhibition of CREB/KISS1 signaling. *Oncotarget* 2016; 7: 35092-35105 [PMID: 27145368 DOI: 10.18632/oncotarget.9042]

133 **Perez-Carbonell L**, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A. MiR-320e is a novel prognostic biomarker in colorectal cancer. *Br J Cancer* 2015; **113**: 83-90 [PMID: 26035698 DOI: 10.1038/bjc.2015.168]

134 **Dong SJ**, Cai XJ, Li SJ. The Clinical Significance of MiR-429 as a Predictive Biomarker in Colorectal Cancer Patients Receiving 5-Fluorouracil Treatment. *Med Sci Monit* 2016; **22**: 3352-3361 [PMID: 27654003 DOI: 10.12659/MSM.900674]

135 **Yang IP**, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH, Wang JY. Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. *J Transl Med* 2016; **14**: 108 [PMID: 27126129 DOI: 10.1186/s12967-016-0856-2]

136 **Rasmussen MH**, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brünner N, Ørntoft TF, Andersen CL. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. *Mol Oncol* 2013; **7**: 637-646 [PMID: 23506979 DOI: 10.1016/j.molonc.2013.02.016]

**P-Reviewer:** Demetrashvili Z, Garg P, Ng QX **S-Editor:** Dou Y

**L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

****

**Figure 1 The way gut microbiota induces CRC.** Several factors affecting the normal behavior of microbiota such as low fiber and high-fat diets. This change might affect the number/types of gut bacteria or cause them to express different kinds of proteins and metabolites. A category of these metabolites could be oncogenic (oncometabolites) and trigger inflammation in gut epithelial cells leading to cancer initiation. Bacterial metabolites also could enhance cancer spreading and metastasis. CRC: Colorectal cancer.

****

**Figure 2 Different pathways through which CRC develops.** CRC: Colorectal cancer.

****

**Figure 3 Different functions of butyrate in protecting against CRC.** CRC: Colorectal cancer; HDAC: Histone deacetylase.

****

**Figure 4 Different gut microbiota generate different oncometabolites.** Bacteroides expresses specific signaling substances to activate toll-like receptor 2 (TLR 2), which functions in two different ways; activation of FOX3 to trigger Treg activation leading to inflammation. The other way is the activation of T helper 17 cells that also triggers inflammation. Flagellin, a product of flagellated bacteria, activates also TLR 5 to activate innate lymphoid cells 3 and then IL 17 and 22 that initiate inflammation. TLR 5 also works on nuclear factor κB to activate miR-21 that has a role in initiating cancer carcinogenesis (CRC). Meanwhile, *Fusobacteria* can stimulate a specific type of TLR that activates nuclear factor of activated T cell *via* calmodulin-based calcineurin to initiate CRC. CRC: Colorectal cancer; IL: Interleukin; ILC: lymphoid cells; NF-κB: Nuclear factor-κB; NFAT: Nuclear factor of activated T cell; TLR: Toll-like receptor; Treg: T regulatory cell.

**Table 1 Gut microbiota are involved in CRC carcinogenesis**

|  |  |  |
| --- | --- | --- |
| Microorganism | Role in CRC initiation/progression | Ref. |
| *Lactobacillus casei BL23* | Immunomodulatory effect *via* downregulation of the IL-22, and an antiproliferative effect, *via* upregulation of caspase-7 and caspase-9 | [109] |
| *Escherichia coli NC101* | Production of colibactin that induces CRC | [110] |
| *Fusobacterium nucleatum* | Activation of β-catenin signaling and induction of oncogenic gene expression that promotes growth of CRC cells *via* the FadA adhesion virulence facto. It produces also the autotransporter protein, Fap2, that has been shown to potentiate the progress of CRC *via* inhibiting immune cell activity | [111] |
| *Eubacterium rectale* | Production of butyrate to induce IL-10, the anti-inflammatory cytokine | [112] |
| *Bacteroides fragilis* | Production of Enterotoxigenic *Bacteroides fragilis* (ETBF) toxin that promotes CRC by modulating the mucosal immune response and inducing epithelial cell changes. ETBF stimulates E-cadherin cleavage and facilitates cell tumor metastasis | [113] |
| *Streptococcus bovis* | Triggering of inflammations, bacteremia, and endocarditis, that leads ultimately to colorectal cancer | [114] |
| *Clostridium septicum* | Production of alpha toxin that binds GPI-anchored cell surface receptors including the human folate receptor as well as the neuronal molecules contactin and Thy-1 (CD90) | [115] |
| *Enterococcus faecalis* | Damaging the colonic epithelial cell DNA | [116] |
| *Bifidobacterium* | Production of β-galactosidases, which has antitumor activity | [117] |
| *Helicobacter pylori* | Induction of inflammatory responses, alteration of gut microflora and release of gastrin, which may contribute to tumor formation | [118] |
| *Faecalibacterium prausnitzii* | Production of butyrate to induce IL-10, the anti-inflammatory cytokine that protects against cancer formation | [119] |
| *Enterotoxigenic bacteroides* | Induction of early-stage carcinogenic, that might lead to early colorectal carcinogenesis | [113] |
| *Clostridium nexile* | Contribution to the anticancer effect of Pseudomonas aeruginosa. It improves also malnutrition in infants | [120] |
| *Fusobacterium varium* | Activate the E-cadherin/β-catenin signaling pathway and association with epigenetic phenotype, such as microsatellite instability and hypermethylation, *via* its strong adhesive and invasive abilities resulting in malignant transformation of epithelial cells | [121] |
| *Actinomyces odontolyticus* | Causes colon actinomycosis only when the epithelial barrier was perished | [122] |
| *Veillonella dispar* | Might be able to enhance the dosage response to CRC chemotherapeutic agents or reduce the side effects of these drugs | [123] |

CRC:Colorectal cancer; ETBF: Enterotoxigenic *Bacteroides fragilis*.

[**Table 2**](http://www.wjgnet.com/1007-9327/full/v24/i27/2949-T1.htm) **A list of representative miRNAs identified in tumor tissues that are of prognostic value in CRC patients**

|  |  |  |
| --- | --- | --- |
| miRNA | Role in CRC | Ref. |
| miR-15a/miR-16 | Their low expression levels were associated with poor disease-free survival and overall survival | [124] |
| miR-17-5p | Its high expression was associated with disease-free survival | [125] |
| miR-21 | Its high level of expression was associated with poor survival and poor therapeutic outcomes | [126] |
| miR-29a | Its elevated level of expression was associated with a longer disease-free survival in stage II CRC patients | [127] |
| miR-34a-5p | Its high expression was correlated with disease-free survival | [128] |
| miR-106a | Its downregulation was associated with shortened overall survival | [125] |
| miR-132 | Its decreased expression level was associated with poorer overall survival and occurrence of distant metastasis especially in liver | [129] |
| miR-150 | Its elevated expression level was associated with longer overall survival. While its low level of expression was associated with poor therapeutic outcome in patients treated with 5-Fluro uracil | [130] |
| miR-195 | Its low expression rate was associated with occurrence of lymph node metastasis and advanced tumor grade/stage | [131] |
| miR-199b | Increased in metastatic CRC tissue compared with non-metastatic CRC tissue. Furthermore, its low expression was associated with longer overall survival | [132] |
| miR-203 | Its elevated expression level was associated with advanced TNM staging and poorer overall survival | [130] |
| miR-320e | Its high expression was associated with poorer overall survival in stage III colon cancer patients | [133] |
| miR-429 | Its overexpression was associated with overall survival; low level of expression was associated with response to 5-Fluro uracil-based chemotherapy | [134] |
| miR-494 | Its elevated expression was associated with shorter DFS and overall survival | [135] |
| miR-625-3p | High expressions were associated with higher overall survival and enhanced response to therapy | [136] |

CRC: Colorectal cancer.